colorectal cancer, Leap Therapeutics

Leap Therapeutics: 2 Cancer Trials Disappoint, But There Is A Silver Lining
Leap Therapeutics, Inc.'s DKN-01 trial results show mixed outcomes in cancer treatment, prompting potential future funding needs. Click for my LPTX stock update.
Leap Therapeutics Shares Slide After Initial Mid-Stage Cancer-Drug Results
Shares of Leap Therapeutics slid after disappointing initial data from two mid-stage clinical trials of its oncology treatment, resulting in the discontinuation of one clinical program.
Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced positive initial data from Part B of the DeFianCe study evaluating sirexatamab (DKN-01) in combination with bevacizumab and chemotherapy as a second-line treatment for patients with advanced colorectal cancer (CRC),
Leap crashes as midphase data mark end of gastric cancer program
Leap Therapeutics has come crashing down to earth. The biotech axed plans to advance into phase 3 in gastric cancer on the basis of midstage data, sending its stock down 60% to below $1, but it is forging ahead in another indication.
Leap Therapeutics Stock Plunges To Record Low After Ending Gastric Cancer Drug Trials, Retail Bets On CRC Pipeline
Shares of Leap Therapeutics, Inc. nosedived more than 70% to an all-time low on Tuesday, making them the top loser across U.S. exchanges. The sharp drop — Leap’s worst intraday fall ever — came after the biotech firm announced it would terminate further development of sirexatamab in gastric cancer trials while shifting its focus to colorectal cancer (CRC).
Leap Therapeutics stock plummets as it will discontinue DisTinGuish study in advanced gastric cancer
Shares of Leap Therapeutics (NASDAQ:LPTX) tumbled 64% in pre-open trading Tuesday as the company announced that its DisTinGuish study of sirexatamab combined with tislelizumab and chemotherapy did not meet the primary progression-free survival (PFS) endpoints for patients with advanced gastric cancer.
Leap scraps late-stage plans for gastric cancer therapy after mid-stage setback
Leap Therapeutics (NASDAQ:LPTX) lost 63% in the premarket on Tuesday after the antibody-based drug developer announced that it would not advance its lead candidate, sirexatamab, in Phase 3 studies for gastric cancer following disappointing data from a mid-stage trial.

Leap Therapeutics cut to Neutral at Baird

The Pharma Letter1d
Leap halts gastric cancer program, changes course
Leap Therapeutics is discontinuing the development of its anti-DKK1 antibody sirexatamab in gastric cancer after the drug ...
Leap reports positive colorectal cancer study results
CAMBRIDGE, Mass. - Leap Therapeutics, Inc. (NASDAQ:LPTX), a clinical-stage biotech company with a market capitalization of $86 million and an overall "Fair" financial health rating according to ...